title: Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.
abstract: A multi-institutional, phase 1 dose-escalation trial of lintuzumab (humanized anti-CD33 antibody; SGN-33, HuM195) was performed in patients with CD33-positive myeloid malignancies. In this study, higher doses than previously tested and prolonged duration of treatment for responding patients were evaluated. Over the dose range of 1.5-8 mg/kg/week, lintuzumab was well tolerated, and a maximum tolerated dose was not defined. The most common adverse event was transient chills with the initial lintuzumab infusion (39%). Responses were observed in 7 of 17 patients with acute myeloid leukemia: morphologic complete remission (n = 4), partial remission (n = 2), and morphologic leukemia-free state (n = 1). Of 14 patients with myelodysplastic syndrome or myeloproliferative diseases, 1 patient had major hematologic improvement and 9 patients had stable disease. In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity.
authors: St. Vincent's Comprehensive Cancer Center, New York, NY, USA.
authors: Azra
authors: A
authors: Raza
authors: Joseph G
authors: JG
authors: Jurcic
authors: Gail J
authors: GJ
authors: Roboz
authors: Michael
authors: M
authors: Maris
authors: Joseph J
authors: JJ
authors: Stephenson
authors: Brent L
authors: BL
authors: Wood
authors: Eric J
authors: EJ
authors: Feldman
authors: Naomi
authors: N
authors: Galili
authors: Laurie E
authors: LE
authors: Grove
authors: Jonathan G
authors: JG
authors: Drachman
authors: Eric L
authors: EL
authors: Sievers
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology*; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D023341:Chills / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D009196:Myeloproliferative Disorders / Q000188:drug therapy*; D012074:Remission Induction; D063268:Sialic Acid Binding Ig-like Lectin 3
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; C477390:lintuzumab